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ABSTRACT 19 
The immune modulating properties of certain bifidobacterial strains, such as Bifidobacterium 20 
longum subsp. longum 35624™ (B. longum 35624), have been well described, although the 21 
strain-specific molecular characteristics associated with such immune regulatory activity are 22 
not well defined. It has previously been demonstrated that B. longum 35624 produces a cell 23 
surface exopolysaccharide and in this study we investigated the role played by this 24 
exopolysaccharide in influencing the host immune response. B. longum 35624 induced 25 
relatively low levels of cytokine secretion from human dendritic cells, whereas an isogenic 26 
exopolysaccharide-negative mutant derivative (termed sEPSneg) induced vastly more 27 
cytokines, including IL-17, which was reversed when exopolysaccharide production was 28 
restored in sEPSneg by genetic complementation. Administration of B. longum 35624 to the T 29 
cell transfer colitis model prevented disease symptoms, whereas sEPSneg did not protect 30 
against the development of colitis, with associated enhanced recruitment of IL-17+ 31 
lymphocytes to the gut. Moreover, intra-nasal administration of sEPSneg also resulted in 32 
enhanced recruitment of IL-17+ lymphocytes to the murine lung. These data demonstrate that 33 
the particular exopolysaccharide produced by B. longum 35624 plays an essential role in 34 
dampening pro-inflammatory host responses to the strain and that loss of exopolysaccharide 35 
production results in the induction of local TH17 responses. 36 
IMPORTANCE 37 
Particular gut commensals, such as B. longum 35624, are known to contribute positively to 38 
the development of mucosal immune cells, resulting in protection from inflammatory 39 
diseases. However, the molecular basis and mechanisms for these commensal-host 40 
interactions are poorly described. In this report, an exopolysaccharide was shown to be 41 
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decisive in influencing the immune response to the bacterium. We generated an isogenic 42 
mutant unable to produce exopolysaccharide, and observed that this mutation caused a 43 
dramatic change in the response of human immune cells in vitro. In addition, mouse models 44 
confirmed that lack of exopolysaccharide production induces inflammatory responses to the 45 
bacterium. These results implicate the surface-associated exopolysaccharide of the B. longum 46 
35624 cell envelope in the prevention of aberrant inflammatory responses. 47 
48 
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INTRODUCTION 49 
 The gut microbiota contributes significantly to host health via multiple mechanisms, 50 
including the digestion of foods, competitive exclusion of pathogens, enhancement of 51 
epithelial cell differentiation and promotion of mucosa-associated lymphoid tissue 52 
proliferation (1, 2). Furthermore, accumulating evidence suggests that the composition and 53 
metabolic activity of the gut microbiota has profound effects on proinflammatory activity and 54 
the induction of immune tolerance within mucosal tissue (3-5). Certain microbes induce 55 
regulatory responses, while others induce effector responses, resulting in the case of healthy 56 
individuals in a balanced homeostatic immunological state, which protects against infection 57 
and controls aberrant, tissue-damaging inflammatory responses (6). 58 
One bacterial strain, which is known to induce tolerogenic responses within the gut, is 59 
Bifidobacterium longum subsp. longum 35624TM (7). Induction of T regulatory (Treg) cells by 60 
the B. longum 35624 strain in mice is associated with protection against colitis, arthritis, 61 
allergic responses and pathogen-associated inflammation (8-12). Administration of this 62 
bacterium to humans increases Foxp3+ lymphocytes in peripheral blood, enhances IL-10 63 
secretion ex vivo, and reduces the level of circulating proinflammatory biomarkers in a wide 64 
range of patient groups (13, 14). A number of host mechanisms have been described, which 65 
contribute to the anti-inflammatory activity of this microbe, including Toll-like receptor 2 66 
(TLR-2) and Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-67 
integrin (DC-SIGN) recognition, and retinoic acid release by dendritic cells (13, 15-17). 68 
However, the bacterial strain-specific structural and/or metabolic factors that contribute to 69 
these protective immune responses have as yet remained elusive. 70 
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A number of different exopolysaccharides from gut microbes have been shown to 71 
induce immune-modulatory effects. Polysaccharide A (PSA) from Bacteroides fragilis 72 
mediates the conversion of naïve CD4+ T cells into Foxp3+ Treg cells that produce IL-10 73 
during commensal colonization. Functional Treg cells are also induced by PSA during 74 
intestinal inflammation, which requires TLR-2 signaling (18). Further studies have reported 75 
that PSA interacts directly with mouse plasmacytoid dendritic cells via TLR-2 and that PSA-76 
exposed plasmacytoid dendritic cells express molecules involved in protection against colitis 77 
and stimulate CD4+ T cells to secrete IL-10 (19). An exopolysaccharide from Bacillus subtilis 78 
prevents gut inflammation stimulated by Citrobacter rodentium, which is dependent on TLR-79 
4 and MyD88 signaling (20). Similarly, protection against C. rodentium infection by 80 
Bifidobacterium breve UCC2003 was dependent on the presence of its exopolysaccharide 81 
(21). Furthermore, it was described that an extracellular polymeric matrix, isolated from 82 
Faecalibacterium prausnitzii, displayed anti-inflammatory activity in the mouse dextran 83 
sodium sulphate colitis model (22).  84 
We recently described that the B. longum 35624 strain-specific EPS gene cluster, 85 
designated as eps624, is responsible for the production of a cell surface-associated 86 
exopolysaccharide, composed of a branched hexasaccharide repeating unit with two 87 
galactoses, two glucoses, galacturonic acid and the unusual sugar 6-deoxytalose (23). The 88 
overall aim of the current study was to determine if the exopolysaccharide produced by B. 89 
longum 35624 is related with the immunoregulatory effects of this microorganism. To address 90 
this aim, we investigated if an isogenic derivative of B. longum 35624, which does not 91 
produce exopolysaccharide, is able to exert similar immunological effects to its parent strain 92 
in vitro and in colitis and asthma mouse models. 93 
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 94 
MATERIALS AND METHODS 95 
Bacterial strains, plasmids and culture conditions. Bacterial strains and plasmids used in 96 
this study are detailed in Table 1. Bifidobacteria were routinely cultured in either de Man 97 
Rogosa and Sharpe medium (MRS; Oxoid Ltd., Basingstoke, Hampshire, United Kingdom) 98 
supplemented with 0.05 % cysteine-HCl or reinforced clostridial medium (RCM; Oxoid Ltd.). 99 
Bifidobacterial cultures were incubated at 37 °C under anaerobic conditions in a Don Whitley 100 
anaerobic Chamber. Escherichia coli strains were cultured in Lysogeny broth (LB; Oxoid 101 
Ltd) at 37 °C with agitation. Where appropriate, growth media contained chloramphenicol 102 
(Cm; 10 μg ml-1 for E. coli and 5 μg ml-1 for B. longum 35624), erythromycin (Em; 100 μg 103 
ml-1 for E. coli), tetracycline (Tet; 10 μg ml-1 for E. coli and 10 μg ml-1 for B. longum 35624), 104 
ampicillin (Amp; 100 μg ml-1 for E. coli ) or kanamycin (Km; 50 μg ml-1 for E. coli). All 105 
antibiotics were obtained from Sigma Aldrich, Dorset, England). The commercially available 106 
B. longum 35624™ culture was provided by Alimentary Health limited (Cork, Ireland).  107 
DNA manipulations. Chromosomal DNA was isolated from bifidobacteria as 108 
previously described (24). Minipreparation of plasmid DNA from E. coli or B. longum 35624 109 
was achieved using the Qiaprep spin plasmid miniprep kit (Qiagen GmBH, Hilden, 110 
Germany). For B. longum 35624 an initial lysis step was incorporated into the plasmid 111 
isolation procedure, cells were resuspended in lysis buffer supplemented with lysozyme (30 112 
mg ml-1) and incubated at 37 °C for 30 min. Restriction enzymes and T4 DNA ligase were 113 
used according to the supplier’s instructions (Roche Diagnostics, Bell Lane, East Sussex, 114 
UK). Synthetic single stranded oligonucleotide primers used in this study were obtained from 115 
Eurofins (Ebersberg, Germany) and are detailed in Table 2. Standard PCRs were performed 116 
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using TaqPCR mastermix (Qiagen), while high fidelity PCR was achieved using PfuII 117 
polymerase (Agilent, Santa Clara, California). B. longum 35624 colony PCRs were performed 118 
according to standard procedures with the addition of an initial incubation step of 95 °C for 5 119 
minutes to perform cell lysis. PCR fragments were purified using the Qiagen PCR purification 120 
kit. Following electroporation of plasmid DNA into E.coli strain EC101, 121 
electrotransformation of B. longum 35624 or sEPSneg was performed essentially as described 122 
by Maze et al. (25) with the following modifications. An overnight culture of B. longum 123 
35624 was sub-cultured twice (first using a 2 % inoculum and then a 1 % inoculum) in MRS 124 
supplemented with 0.05 % cysteine-HCl and 0.2 M sucrose prior to inoculating (4%) 125 
modified Rogosa medium supplemented with 0.05 % cysteine-HCl, 1% (w/v) glucose and 0.2 126 
M sucrose. Bacteria were grown until the OD600 had reached 0.3-0.4, after which cells were 127 
harvested by centrifugation (6,500 rpm, 10 min, and 4 °C) and washed twice using 1 mM 128 
ammonium citrate buffer (pH 6.0) supplemented with 0.5 M sucrose. An additional 129 
centrifugation step (9,800 *g, 10 min, and 4 °C) was included to concentrate the competent 130 
cells. For electroporation 5 µl of plasmid DNA was mixed with 50 µl of competent cells, 131 
transferred into an electroporation cuvette with 0.2 cm inter-electrode distance and pulsed at 132 
2.5 kV, 25 µF and 200 Ω using a Gene Pulser II Electroporation System (Biorad, Hercules, 133 
California USA). For recovery, 800 µl of RCM supplemented with 0.05 % L-cysteine 134 
hydrochloride were added to bacteria and incubated anaerobically for 2.5 h at 37 °C. 135 
Transformations were plated on reinforced clostridial agar (RCA) plates supplemented with 136 
appropriate concentrations of relevant antibiotics and incubated 2-3 days anaerobically at 37 137 
°C. The correct orientation and integrity of all constructs was verified by PCR and subsequent 138 
DNA sequencing, which was performed at Eurofins (Ebersberg, Germany).  139 
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Construction of sEPSneg. An internal 583 bp fragments of the pgt624 gene was 140 
amplified by PCR using B. longum 35624 chromosomal DNA as a template and the 141 
oligonucleotide primers BI0342F_HindIII and BI0342R_XbaI. The PCR product generated 142 
was ligated to pORI19, an Ori+ RepA- integration plasmid (26), using the unique HindIII and 143 
XbaI restriction sites that were incorporated into the primers for the pgt fragment-144 
encompassing amplicon, and introduced into E. coli EC101 by electroporation. Recombinant 145 
E. coli EC101 derivatives containing pORI19 constructs were selected on LB agar containing 146 
Em, and supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) (40 147 
μg ml-1) and IPTG (isopropyl-β-D galactopyranoside) (1 mM). The expected genetic structure 148 
of the recombinant plasmid, designated pORI19-pgt, was confirmed by restriction mapping 149 
prior to subcloning of the Tet resistance antibiotic cassette, tet(W), from pAM5 (27) as a SacI 150 
fragment into the unique SacI site on pORI19-pgt. The expected structure of a single 151 
representative of the resulting plasmid, designated pORI19tet(W)_pgt, was confirmed by 152 
restriction analysis. The plasmid was introduced into E. coli EC101 harbouring pNZ-M.1185 153 
(this is a plasmid expressing a B. longum 35624-encoded methylase) by electroporation, and 154 
transformants were selected based on Em and Tet resistance. Methylation of the resulting 155 
plasmid complement of such transformants by the M.1185 (isoschizomer of M.EcoRII) was 156 
confirmed by their observed resistance to EcoRII restriction. Plasmid preparations of 157 
methylated pORI19tet(W)_pgt were introduced by electroporation into B. longum 35624 with 158 
subsequent selection on RCA plates supplemented with Tet. 159 
Construction of sEPScomp. For the construction of plasmid pBC1.2_pgt624 +BI0343, a 160 
DNA fragment encompassing pgt624 plus the downstream located gene with locus tag BI0343 161 
and the presumed promoter region was generated by PCR amplification from chromosomal 162 
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DNA of B. longum 35624 using PfuII polymerase and primer combinations BI0342FSalI and 163 
BI0343EcoRI, where SalI or EcoRI restriction sites were incorporated at the 5’ ends of the 164 
forward primer, and reverse primer, respectively. Amplicons were digested with SalI, and 165 
EcoRI, and ligated into similarly digested pBC1.2 prior to introduction into E. coli XL1blue 166 
by electroporation and subsequent selection of transformants on LB agar supplemented with 167 
Tet and Amp. The integrity of positive clones was confirmed by sequencing and one selected 168 
clone designated pBC1.2 pgt+BI0343 was introduced into sEPSneg by electroporation with 169 
subsequent selection of transformants on RCA supplemented with Tet and Cm. The resultant 170 
sEPSneg strain harboring pBC1.2 pgt+BI0343 was designated sEPScomp. 171 
Electron Microscopy. After culture in MRS medium, bacteria were gently rinsed in 172 
Piperazine-N,N-bis-2-ethane sulphonic acid (PIPES) buffer (0.1 M, pH 7.4) before being 173 
fixed in 2.5 % glutaraldehyde in PIPES buffer for 5 min. The samples were rinsed twice (2 174 
min each time) in PIPES buffer and post-fixed with 1 % osmium tetroxide in 0.1 M PIPES 175 
buffer (pH 6.8), for 60 min in the dark. The samples were rinsed three times in double 176 
distilled water (2 min each wash) before dehydration through an ethanol series (50, 70, 96, 177 
and 100 %) for 5 min each. All fixation and washing steps were carried out at room 178 
temperature. Following dehydration, the samples were critically point dried in a POLARON 179 
E3100 critical point drier (Agar Scientific, Stansted, UK), and coated with 10 nm of 180 
gold/palladium (80/20) using a Baltec MED 020 unit (Baltec, Buchs, Liechtenstein). Bacterial 181 
preparations were examined using a Hitachi S-4700 scanning electron microscope (SEM), 182 
operated in secondary electron detection mode (3 kV, 40 μA) and images captured with 183 
Quartz PCI (Quartz Imaging Corporation, Vancouver, Canada). 184 
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Exopolysaccharide isolation. The exopolysaccharide was isolated as previously 185 
described (23). Briefly, following harvesting of B. longum 35624 cells, which were grown on 186 
agar plates to minimize carryover of media components, an exopolysaccharide solution was 187 
generated by agitating the cells in PBS. The harvested exopolysaccharide solution was mixed 188 
with ethanol and the exopolysaccharide aggregated at the center of the surface of the ethanol 189 
solution, which facilitated harvesting of the exopolysaccharide without the need for 190 
centrifugation. The exopolysaccharide aggregations were taken with a spatula, resuspended in 191 
water and dialysed against water to remove contaminants and residual ethanol. The 192 
exopolysaccharide was applied 2 times on Bakerbond SPE C18 columns (Avantor, Deventer, 193 
The Netherlands) as indicated by the manufacturer using a HyperSep-96™ vacuum manifold 194 
(Thermo Scientific, Waltham, USA). The flow-through fraction was collected and filtered 195 
through 0.45 µm syringe filters. Quantification of total carbohydrate levels was performed as 196 
previously described (28) using a phenol-sulphuric acid method in microplate format. The 197 
absence of contaminating proteins was confirmed by measuring the total soluble protein 198 
content of the exopolysaccharide preparation using the BCA protein quantification kit 199 
(Thermo Scientific) according to manufacturer’s instructions. Bovine serum albumin was 200 
used for generation of standards. Lipopolysaccharide contamination was monitored using the 201 
pyrogene recombinant factor C assay (Lonza, Bettlach, Switzerland). 202 
In vitro immune assays. Human blood was purchased from the Swiss blood bank 203 
(Blutspendezentrum, Basel, Switzerland), which obtains the blood following appropriate 204 
screening and consenting of volunteers. Blood samples were anonymized and coded prior to 205 
leaving the blood bank. Research procedures on human blood were performed in accordance 206 
with Swiss law (ethical approval number KEK Nr. 19/08). All experiments with human 207 
blood-derived cells were conducted under biosafety level 2 conditions. Peripheral blood 208 
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mononuclear cells (PBMCs) were isolated from healthy donors using density gradient 209 
centrifugation. Human monocyte-derived dendritic cells (MDDCs) were differentiated with 210 
1000 IU ml-1 GM-CSF (Peprotech, London, UK) and 1000 IU ml-1 IL-4 (Novartis, Basel, 211 
Switzerland) from purified CD14+ cells using MACS separation (Miltenyi Biotec, Bergisch 212 
Gladbach, Germany). Bacterial strains for in vitro assays were cultured in MRS medium 213 
supplemented with 0.05 % L-cysteine for 48 hours under anaerobic conditions at 37°C. Cells 214 
were harvested and washed once with sterile PBS by centrifugation at 6,500 rpm for 10 215 
minutes. Bacterial cell number was determined by microscopy using a Petroff-Hausser 216 
chamber and bacteria were diluted as appropriate in PBS for incubation with human cells. 217 
PBMCs and MDDCs were stimulated for 24 h at 37°C, 5 % CO2 with bacterial strains at a 218 
concentration of 50 bacterial cells to 1 PBMC or MDDC. Human and bacterial cell co-219 
cultures were performed in complete RPMI-1640 (cRPMI) medium (Sigma, Buchs, 220 
Switzerland) supplemented with 10% fetal bovine serum (Sigma), penicillin (100 Units ml-1) 221 
and streptomycin (0.1 mg ml-1) (Sigma). Purified exopolysaccharide from B. longum 35624 222 
was also added (final concentration 100 μg/ml) to PBMC cultures (in duplicate) stimulated 223 
with sEPSneg. Cytokine concentrations were measured using the Bio-Plex Multiplex System 224 
(Biorad). For human dendritic cells staining, the following anitibodies were used: PE-Cy7 225 
anti-human CD274 (PD-L1), APC anti-human CD273 (PD-L2) and Pacific Blue anti-human 226 
CD11c (eBioscience, Vienna, Austria).  THP-1-BlueTM NF-κB monocyte cell line (Invivogen, 227 
San Diego, USA) was maintained and sub-cultured in cRPMI medium (Sigma) in presence of 228 
200µg/ml Zeocin (Invivogen). For the co-culture experiment with bacteria, 105 cells/well 229 
were seeded in a 96 well-plate in a total volume of 200 µl/well of cRPMI medium. The cells 230 
were stimulated over a range of different bacterial concentrations for 24 h and activation of 231 
NF-κB/AP-1 pathway was evaluated by Quanti-BlueTMassay according to the manufacturer’s 232 
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instructions. In addition, MDDCs were stimulated with different bacterial strains and NF-κB 233 
phosphorylation measured over a time course. MDDCs were lysed using Bio-Plex Pro cell 234 
signaling reagent kit (Biorad) and cell lysates were stored at -80°C until analysis. Protein 235 
concentration was determined using Bio-Rad’s DCTM protein assay and equal amounts of 236 
protein were used to measure NF-κB p65 (Ser536) in the Bio-Plex Pro™ Magnetic Cell 237 
Signaling Assay (Biorad). Results are expressed as MFI (mean fluorescence intensity). 238 
T cell transfer colitis model. C.B-17 severe combined immunodeficient (SCID and 239 
BALB/c female mice (8-12 weeks of age) were obtained from Charles River (Sulzfeld, 240 
Germany) and maintained under specific pathogen free conditions. The animals were housed 241 
at the AO Research Institute, Davos, Switzerland, in individually ventilated cages for the 242 
duration of the study, and all experimental procedures were carried out in accordance with 243 
Swiss law (Permit number: 2013_32). Colitogenic CD4+CD25-CD45RBhi cells were isolated 244 
from BALB/c donor mouse spleens using the MACS Miltenyi system (depletion of 245 
CD4+CD25+ cells followed by positive selection of CD45RB FITC-labeled cells). At day 0, 246 
colitis was induced by intraperitoneal transfer of 4 x 105 cells per C.B-17 SCID mouse (8 247 
mice per group). Bacterial cells were prepared as described above and counted using 248 
microscopy (Petroff-Hausser chamber) prior to dilution in sterile PBS.  1 x 109 B. longum 249 
35624 cells, or its isogenic derivatives, were administered to each mouse by intragastric 250 
gavage (total volume of 200 µl). Bacteria were gavaged from the beginning of the study (day 251 
0) and continued to be gavaged every second day until animals were euthanized at the end of 252 
the study. Sixteen days after study initiation, disease severity scores were recorded, while 253 
animal weights were monitored every day. Disease severity scores included feces condition ( 254 
1 - wet; 2 - diarrhea; 3 - bloody diarrhea or rectal prolapse), activity (1 - isolated, abnormal 255 
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position; 2 - huddled, hypoactive or hyperactive; 3 – unconscious), coordination of movement 256 
(1 - slightly uncoordinated; 2 – very uncoordinated; 3 – paralysis) and fur quality (1 – reduced 257 
grooming;  2 – disheveled; 3 - hair loss). Gut transit was determined by quantifying fecal B. 258 
longum 35624 levels by PCR. B. longum 35624 specific primers were designed using Primer3 259 
software (http://simgene.com/Primer3). The primers, designated 2420t (Forward: CAG TGG 260 
GGT GCG ACT ACA; Reverse: GCG CGA ACC AGA AGA TGT) generated a 494 bp 261 
amplicon. Bacterial DNA from fecal samples was extracted using QIAamp DNA Stool Mini 262 
Kit (Qiagen). DNA was quantified using Nanodrop (Thermo Scientific) and 100 ng of total 263 
DNA was assayed using SYBR Green PCR Master Mix (Biorad). The  thermal  cycling  264 
conditions  consisted of an initial denaturation step of 15 min at 95˚C, followed by 30 cycles 265 
of denaturation at 94˚C for 45 sec, annealing for 45 sec at 56˚C, and extension at 72˚C for 45 266 
sec.  B. longum 35624 DNA concentrations were quantified using the absolute quantitation 267 
protocol of the ABI 7900 Fast real-Time PCR system (Applied Biosystem, CA, USA). In a 268 
parallel experiment, BALB/c healthy mice (6 mice per group) were gavaged with B. longum 269 
35624 or its isogenic derivative for 3 weeks, as described above for the colitis study.  270 
 Following euthanasia on day 26, mesenteric lymph nodes were isolated in order to 271 
obtain single cell suspensions. Lymph nodes were mechanically disrupted using a syringe 272 
plunger to grind the nodes on a nylon cell strainer (70 µm). The strainer was washed with 273 
PBS and the single cell suspensions were centrifuged at 300 g for 10 minutes. Cell pellets 274 
were resuspended in 1 ml of cRPMI medium (Sigma) and cells were counted using a Scepter 275 
Cell Counter (Millipore, Billerica, MA, USA). Cells were diluted to a final density of 276 
1x106cells ml-1 in cRPMI and cells were dispensed in propylene tubes to perform FACS 277 
staining. Lamina propria mononuclear cells were isolated as described previously (29) 278 
following removal of epithelial cells and collagenase VIII/DNaseI (Roche) digestion of the 279 
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tissue. At the end of the process, cells were counted using the Scepter Cell Counter 280 
(Millipore) and diluted to a final concentration of 1x106 cells ml-1 in cRPMI in propylene 281 
FACS staining tubes. 282 
OVA respiratory allergy model. Female BALB/c mice (8-12 weeks of age) were 283 
obtained from Charles River and were maintained under specific pathogen free conditions at 284 
the AO Research Institute, Davos, Switzerland, in individually ventilated cages for the 285 
duration of the study. All experimental procedures were carried out in accordance with Swiss 286 
law (Permit number: 2013_20). 8 mice per group were used in this model. Three 287 
intraperitoneal immunizations with 50 µg of ovalbumin (OVA, Grade V>98%, Sigma) 288 
emulsified in Imject™ Alum Adjuvant (Life Technologies, Carlsbad, California, USA) were 289 
performed on days 0, 14 and 21, followed by OVA aerosol challenges on days 26, 27 and 28. 290 
On days 19, 25 and 27, mice received B. longum 35624 or sEPSneg intra-nasally (~1x109 291 
bacteria per dose in a total volume of 50 µl of PBS). Bacterial cells were prepared as 292 
described above. Control animals received three intraperitoneal injections with Alum adjuvant 293 
(without OVA) on days 0, 14 and 21, followed by OVA aerosol challenges on days 26, 27 and 294 
28. Control animals also received 50 µl of PBS intra-nasally on days 19, 25 and 27. All mice 295 
were sacrificed at day 29 for isolation of lung tissue and flow cytometric staining. Lung-296 
derived single cell suspensions were obtained using a combination of enzymatic digestion 297 
(lung dissociation kit, Miltenyi) and mechanical dissociation with a gentleMACS Dissociator 298 
(Miltenyi), according to the manufacturer’s protocol. Lung cells were plated at 1x106 cells/ml 299 
in complete RPMI (Sigma) and stimulated ex vivo with 50 µg/ml OVA grade VI (Sigma) or 300 
with 500 ng/ml LPS (Sigma) for 48 hours and cytokine secretion quantified by the Bio-Plex 301 
Multiplex System (Biorad). 302 
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Flow cytometry. All flow cytometry analyses were performed on the Gallios Flow 303 
Cytometer (Beckman Coulter, Brea, USA). Mesenteric lymph node or lung single cell 304 
suspensions were stimulated with PMA and ionomycin at 50 ng ml-1 and 500 ng ml-1, 305 
respectively, for 4 hours in presence of Brefeldin A (eBioscience). Viability dye eFluor780 306 
(eBioscience) and the following surface staining antibodies were used: PE-Cy7 anti-mouse 307 
CD3 and Pacific Blue anti-mouse CD4 (Biolegend, San Diego, California USA). Cells were 308 
stained for intracellular cytokines using PE anti-mouse IL-10, Alexa Fluor488 anti-mouse/rat 309 
IL-17A and PerCP-Cy5.5 anti-mouse IFN-γ after fixation and permeabilization (Intracellular 310 
Fixation & Permeabilization Buffer Set, eBioscience). Lamina propria cells were in addition 311 
stained for the gut homing molecule CCR9 using Alexa Fluor647 anti-mouse CD199 (CCR9) 312 
from Biolegend. 313 
Statistical analysis. Unless otherwise indicated, data are presented as box-and-314 
whisker plots with the median value and max/min values illustrated. In experiments with 315 
technical replicates, the mean was calculated from the technical replicates for each donor and 316 
only the mean value was used for the statistical analysis. The Mann–Whitney U test was used 317 
for the nonparametric statistical analysis of differences between two groups. For analysis of 318 
more than two groups, statistical significance was determined using the Kruskal–Wallis test 319 
and Dunn’s multiple comparison test.  A two-way ANOVA was used to compare groups over 320 
time. A p-value less than 0.05 was considered statistically significant.  321 
 322 
RESULTS 323 
Generation of an isogenic exopolysaccharide-negative derivative of B. longum 35624, 324 
designated sEPSneg, by insertion mutagenesis. In order to determine the role, if any, of the 325 
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exopolysaccharide in the reported immunomodulatory activities of the B. longum 35624 326 
strain, we set out to generate an isogenic derivative of this strain that was unable to produce 327 
this cell surface-associated glycan exopolymer. For this purpose, we employed a mutagenesis 328 
strategy that was based on previously described methods (30). The particular mutagenesis 329 
strategy employed for B. longum 35624 involved the heterologous expression of a B. longum 330 
35624-encoded DNA methylase in E. coli strain EC101 so as to methylate any plasmid DNA 331 
in this latter cloning host. When such methylated plasmid DNA is subsequently introduced 332 
into B. longum 35624, it will be protected from digestion by the native restriction-333 
modification systems encoded by the latter strain and will therefore allow homology-guided, 334 
site-directed mutagenesis as has been described previously (30). Employing this strategy, we 335 
created an insertion mutation in the first gene of the eps624 cluster, i.e. pgt624, encoding the 336 
predicted priming glycosyl transferase (pGT), resulting in an isogenic derivative of B. longum 337 
35624, which was designated sEPSneg.  338 
In order to assess if the sEPSneg mutant had, as would be expected, lost its ability to 339 
produce exopolysaccharide we performed electron microscopy analysis, which indeed 340 
revealed that the ‘stringy’ sEPS layer present on the parent strain B. longum 35624 is absent 341 
on EPSneg, thus confirming its exopolysaccharide-deficient phenotype (Fig. 1). Furthermore, 342 
and in contrast to the parent strain B. longum 35624, the EPSneg strain exhibits a so-called 343 
dropping phenotype when grown in liquid medium (i.e. the EPSneg strain was found to 344 
sediment during growth in liquid medium, but the B. longum 35624 strain remained in 345 
suspension). A similar phenotype was observed for exopolysaccharide-negative variants of B. 346 
breve UCC2003 and Bifidobacterium animalis subs. lactis (21, 31), thereby substantiating the 347 
loss of exopolysaccharide production. To ensure that the observed phenotype is directly 348 
linked to the inactivation of pgt624, the adjacent and co-transcribed genes pgt624 and BI0343 349 
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were cloned together with the presumed promoter sequence in plasmid pBC1.2, after which 350 
the resultant construct was introduced in the sEPSneg strain. The resulting strain, designated 351 
sEPScomp, was shown to produce exopolysaccharide (Fig. 1). A similar complementation 352 
approach was previously described (32, 33). The sEPSneg and sEPScomp mutants grew more 353 
slowly compared to the parent strain B. longum 35624, likely due to the presence of 354 
antibiotics in their culture media, but by 38 hours of culture all bacteria were at similar 355 
numbers and had reached stationary phase (Supplementary Fig. S1). 356 
In vitro responses to B. longum 35624, sEPSneg and sEPScomp. The wild-type strain 357 
B. longum 35624 and its derivatives sEPSneg or sEPScomp were co-incubated with human 358 
PBMCs for 24 hours, followed by analysis of cytokine secretion in cell-free supernatants. As 359 
compared with B. longum 35624, the sEPSneg strain was shown to induce higher levels of IL-360 
12p70, IFN-γ and IL-17 secretion, with comparable induction of IL-10 (Fig. 2A). The 361 
sEPScomp strain induced similar levels of cytokine secretion as B. longum 35624, confirming 362 
that enhanced pro-inflammatory cytokine secretion is specifically associated with the lack of 363 
exopolysaccharide production. The addition of isolated exopolysaccharide to the co-cultures 364 
significantly reduced IL-12p70 and IFN-γ secretion in response to the sEPSneg strain, but did 365 
not alter IL-17 or IL-10 responses to the sEPSneg  strain (Fig. 2B).  366 
Similarly to PBMCs, human MDDCs were co-incubated with B. longum 35624 or 367 
sEPSneg strains, and cytokine secretion was measured after a 24 hour exposure. Secreted IL-368 
17, IL-6 and TNF-α levels, but not IL-10, were all shown to be significantly higher for the 369 
sEPSneg-stimulated MDDCs, compared to B. longum 35624 -stimulated MDDCs (Fig. 3A). In 370 
contrast, no differences were found in the B. longum 35624 or sEPSneg –induced expression of 371 
the MDDC inhibitory molecules programmed death-ligand 1 (PD-L1) and PD-L2, which bind 372 
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to PD-1 on activated lymphocytes and play an important role in down-regulating the immune 373 
system (Fig. 3B).  374 
Activation of the transcription factor NF-κB is critical for the induction of 375 
inflammatory genes, including cytokines. Thus, we measured NF-κB activation in the 376 
monocyte cell line THP-1, containing a SEAP reporter for NF-κB and AP-1 activation. The 377 
sEPSneg strain was shown to induce higher levels of NF-κB/AP-1 activation, compared to B. 378 
longum 35624-stimulated THP-1 cells (Fig. 3C). To confirm this result, NF-κB 379 
phosphorylation was measured in MDDCs over time, following exposure to bacteria. Both B. 380 
longum 35624 and sEPSneg strains induced similar levels of NF-κB phosphorylation at early 381 
time points (Fig. 3D). However, sustained high levels of phosphorylated NF-κB were 382 
observed at later time points for the sEPSneg-stimulated MDDCs, which were not observed for 383 
B. longum 35624-stimulated cells. 384 
Taken together, these results suggest a role for this exopolysacharide in preventing in 385 
vitro inflammatory responses to B. longum 35624. 386 
The sEPSneg strain does not protect against colitis development. Colitis was 387 
induced in SCID mice by adoptively transferring CD4+CD25-CD45RBhi lymphocytes. Mice 388 
were administered B. longum 35624, sEPSneg or sEPScomp daily by oral gavage. As previously 389 
described, B. longum 35624 treatment prevented weight loss and disease symptoms in this 390 
model (34). However, mice treated with the sEPSneg strain exhibited significant weight loss 391 
and severe disease symptoms, while restoration of EPS production in the sEPScomp strain 392 
promoted a similar response as to B. longum 35624 (Fig. 4A). Following euthanasia, the 393 
colon:body weight ratio was significantly higher in animals administered the sEPSneg strain, 394 
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while macroscopically the colons of these mice appeared severely inflamed with visible 395 
necrotic regions, which was not observed when animals had been administered B. longum 396 
35624 (Fig. 4B). Within the mesenteric lymph nodes, there were significantly more IL-17+ 397 
lymphocytes in animals administered the sEPSneg, with a trend towards increased numbers of 398 
IFN-γ+ lymphocytes, which was not statistically significant (Fig. 4C). No significant 399 
difference in IL-10+ lymphocytes was observed. No differences in the gastrointestinal transit 400 
of B. longum 35624 or the sEPSneg derivative was observed (Supplementary Fig. S2). 401 
The administration of the sEPSneg strain to healthy immunocompetent animals did not result 402 
in gastrointestinal inflammation, indicating that the sEPSneg mutant did not induce colitis in 403 
healthy animals. However, administration of sEPSneg did provoke a trend in an increased 404 
percentage of IL-17+ and IFN-γ+ lymphocytes, associated with an increase in CCR9+ T cells, 405 
within the lamina propria of healthy animals, although these differences did not reach 406 
statistical significance (Supplementary Fig. S3). These data suggest that an inflamed micro-407 
environment, such as that present in the SCID model, is required for sEPSneg to exert its TH17-408 
enhancing effects. 409 
sEPSneg exacerbates IL-17 responses within the lung. In order to further assess the 410 
ability of sEPSneg to promote IL-17 responses in vivo, we utilized the ovalbumin (OVA) 411 
sensitization and respiratory challenge model, as we and others previously evidenced potent 412 
TH17 responses within the lungs of challenged animals (35). Either the B. longum 35624 or its 413 
isogenic derivative sEPSneg were administered intra-nasally to examine the influence of these 414 
strains on IL-17 responses within the lung. OVA sensitization and challenge resulted in an 415 
increased percentage of IL-17+ lymphocytes within lung tissue, compared to control animals 416 
(Fig. 5A). Exposure to the B. longum 35624 strain did not influence the percentage of IL-17+ 417 
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lymphocytes within the lung, however, exposure to sEPSneg significantly increased the 418 
percentage of IL-17+ lymphocytes (Fig. 5A). Single cell suspensions were generated from the 419 
lungs of all animals challenged as indicated above, and these lung cells were re-stimulated ex 420 
vivo with OVA or LPS to assess IL-17 secretion. OVA sensitized and challenged animals 421 
displayed increased ex vivo secretion of IL-17 to both OVA and LPS stimulation, compared to 422 
non-sensitized animals, suggesting that innate TLR-4 responses to LPS and allergen-specific 423 
lymphocyte responses to OVA are increased in the inflamed lungs of allergic animals (Fig. 424 
5A). The in vivo exposure to B. longum 35624 did not alter the ex vivo secretion of IL-17 by 425 
lung cells stimulated with either LPS or OVA. However, if animals had been exposed to 426 
sEPSneg in vivo previously, the isolated lung cells secreted significantly more IL-17 ex vivo in 427 
response to both TLR-4 stimulation with LPS and allergen restimulation with OVA (Fig. 5A). 428 
Thus, ex vivo secretion of IL-17 and the percentage of IL-17+ cells within lung tissue correlate 429 
with the highest levels for both assay systems being observed for sEPSneg-treated animals.  430 
OVA sensitization and challenge resulted in an increased percentage of IFN-γ+ 431 
lymphocytes within lung tissue, compared to control animals (Fig. 5A). Exposure to the B. 432 
longum 35624 strain prevented the increase in the percentage of IFN-γ+ lymphocytes within 433 
the lung, which was not observed following exposure to the sEPSneg strain (Fig. 5B). Re-434 
stimulation of lung single cell suspensions ex vivo with OVA or LPS did not result in 435 
significant levels of IFN-γ being secreted and no statistically significant differences were 436 
observed between the groups (Fig. 5B).  437 
OVA sensitization and challenge resulted in an increased percentage of IL-10+ 438 
lymphocytes within lung tissue and exposure to B. longum 35624 or the sEPSneg strains 439 
further increased the percentage of IL-10+ lymphocytes within the lung (Fig. 5C). Re-440 
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stimulation ex vivo was also associated with increased secretion of IL-10 following in vivo 441 
exposure to B. longum 35624 or the sEPSneg strains (Fig. 5C). 442 
These findings suggest that the absence of the exopolysaccharide on B. longum 35624 443 
promotes TH17 responses in the inflamed lung, similar to the effects described above for the 444 
inflamed gut. 445 
 446 
DISCUSSION 447 
In order to avoid immune-mediated destruction of mucosal tissues, the host can activate 448 
regulatory mechanisms that can block proinflammatory responses to commensal microbes 449 
present on mucosal surfaces. Bifidobacteria comprise a significant proportion of the gut 450 
microbiota and many strains are currently used as probiotics. However, the precise 451 
mechanisms by which such bifidobacteria interact with host immune cells are not fully 452 
understood. In this report we describe that the presence of a cell surface-associated 453 
exopolysaccharide produced by B. longum 35624 modulates cytokine secretion and NF-κB 454 
activation in vitro, while in murine models exposure to a B. longum 35624 derivative unable 455 
to synthesize exopolysaccharide promotes TH17 responses both within the gut and the lung. 456 
Bifidobacterial cell surface-associated exopolysaccharides have previously been 457 
proposed to (i) mediate some of their health-promoting benefits, (ii) contribute to their 458 
tolerance of the harsh conditions within the gut, and (iii) to influence composition of the gut 459 
microbiome through their use as a fermentable substrate by other microbes (36-39). In 460 
general, bacterial exopolysaccharide consists of repeating mono- or oligosaccharide subunits 461 
connected by varying glycosidic linkages, which are structurally very diverse, and which may 462 
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contribute to strain-specific traits due to the expected structural and therefore functional 463 
diversity of such molecules. Of note, pathogen-associated exopolysaccharides have long been 464 
known to be critical in host–microbe interactions, where they facilitate adherence and 465 
colonization within the human host, with additional immunomodulatory effects (40, 41). 466 
Exopolysaccharides can also mediate the beneficial immune effects associated with certain 467 
commensal microbes. As already mentioned, a strong modulator of intestinal immune 468 
responses is PSA from B. fragilis, which is well described to influence lymphocyte 469 
polarization and PSA suppresses IL-17 production by intestinal immune cells (42-44). In line 470 
with data presented in this manuscript, exopolysaccharide gene knockout mutants of 471 
Lactobacillus casei Shirota induced significantly more pro-inflammatory cytokine secretion 472 
from a mouse macrophage cell line, compared to wild-type cells (45). In addition, the 473 
cytokine response of PBMCs to two isogenic strains of B. animalis subsp. lactis that differ 474 
only in their exopolysaccharide-producing phenotype suggest that the mucoid strain could 475 
have higher anti-inflammatory activity (31). The data presented in this manuscript are in 476 
agreement with these previous reports and further supports the concept that 477 
exopolysaccharides from bifidobacteria may elicit immune-modulatory activities. 478 
Interestingly, the induction of PD-L1 and PD-L2 on dendritic cells was similar for the 479 
wild type B. longum 35624 strain and its isogenic derivative sEPSneg. Similarly, the induction 480 
of IL-10 was not negatively impacted by the loss of exopolysaccharide from the bacterium. 481 
This suggests that not all immune-regulatory effects induced by B. longum 35624 are 482 
mediated solely by exopolysaccharide. The bifidobacterial cell wall is a complex arrangement 483 
of macromolecules, consisting of a thick peptidoglycan layer that surrounds the cytoplasmic 484 
membrane, which is decorated with other glycopolymers, such as (lipo)teichoic acids, 485 
polysaccharides and proteins, all of which may influence the immune response (46, 47) A few 486 
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examples include the cell wall-associated proteins p40 and p75 from L. casei ssp. rhamnosus 487 
GG, the S-layer protein from L. acidophilus, or the STp peptide from L. plantarum (48-50) .  488 
TH17 cells are a subset of CD4+ T helper cells that mediate protective immunity to 489 
extracellular bacterial and fungal pathogens, predominantly at epithelial surfaces (51). 490 
Polarization of naïve T cells into TH17 cells occurs following T-cell antigen receptor 491 
recognition of an MHC class II-bound peptide in the presence of cytokines including TGF-β1, 492 
IL-6 or IL-1β (52, 53). While TH17 cells are required for protective immunity, these cells 493 
massively infiltrate the inflamed intestine of inflammatory bowel disease patients, where they 494 
produce IL-17 and other cytokines, triggering and amplifying the inflammatory process (54). 495 
Our data suggests that the B. longum 35624 strain-associated exopolysaccharide prevents the 496 
induction of a TH17 response to this bacterium. Multiple mechanisms may be involved in this 497 
process. For example the exaggerated induction of cytokines, including IL-6, from dendritic 498 
cells may support TH17 lymphocyte polarization and development. Support for this 499 
hypothesis can be seen when we restimulate OVA-specific T cells with OVA and we observe 500 
increased secretion of IL-17 when the lungs were previously exposed to sEPSneg. These OVA-501 
specific T cells are not reacting to bifidobacteria-associated antigens, but more IL-17 is 502 
secreted upon OVA challenge suggesting that it is the cytokine microenvironment, provided 503 
by innate cells such as dendritic cells, that is supporting excessive TH17 development. The 504 
observation that addition of purified exopolysaccharide to sEPSneg-stimulated PBMCs 505 
suppresses the exaggerated IL-12p70 and IFN-γ secretion, but not IL-17 secretion, also 506 
suggests that multiple mechanisms may be involved. Future studies will determine if it is the 507 
exopolysaccharide itself that can directly inhibit TH17 responses by binding to host receptors, 508 
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or if the exopolysaccharide is simply masking TH17-promoting molecules on the surface of 509 
this bacterium. 510 
In conclusion, we have identified a novel immunoregulatory activity associated with 511 
the presence of a exopolysaccharide in the human commensal B. longum 35624 strain. Our 512 
findings suggest that this exopolysaccharide is required to prevent a potent tissue-damaging 513 
TH17 response to a commensal bacterium. Accordingly, our data on the B. longum 35624-514 
associated exopolysaccharide corroborates, and expands, the published concept that 515 
exopolysaccharides produced by certain lactic acid bacteria and bifidobacteria may elicit 516 
immune-modulatory activities (55), which are important for appropriate host-microbe 517 
communication. 518 
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FIGURE LEGENDS 712 
Figure 1. B. longum 35624 electron microscopy 713 
Representative scanning electron microscopy (SEM) images for the B. longum 35624 parent 714 
strain (A, upper panel) and its isogenic derivatives, sEPSneg mutant (B, middle panel) and 715 
sEPScomp mutant (C, bottom panel) are illustrated. Arrows indicate the ‘stringy’ layer of 716 
extracellular polysaccharide visible on the B. longum 35624 parent strain and sEPScomp strain . 717 
Scale bars are indicated at the bottom right of each panel. 718 
 719 
Figure 2. PBMC cytokine response to bacterial strains 720 
(A) PBMCs from 6 healthy donors were stimulated with B. longum 35624 or its isogenic 721 
derivatives sEPSneg or sEPScomp (50 bacteria:1 PBMC) for 24 hours and cytokine secretion 722 
into the culture supernatant was quantified. Data are presented as box-and-whisker plots with 723 
the median value and max/min values illustrated. Statistical significance was determined 724 
using the Kruskal–Wallis test and Dunn’s multiple comparison test (*p<0.05). (B) Effect of 725 
adding isolated exopolysaccharide on sEPSneg strain-induced PBMC secretion of IL-12p70, 726 
IFN-gamma, IL-17 and IL-10. Each line connects the data from the same donor. The Mann–727 
Whitney U test was used for the statistical analysis (*p<0.05 versus the sEPSneg strain alone). 728 
 729 
Figure 3. MDDC response to bacterial strains 730 
MDDCs were generated from 4 healthy donors and were stimulated with B. longum 35624 or 731 
its isogenic derivative sEPSneg (50 bacteria:1 MDDC) for 24 hours. Cytokine secretion into 732 
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the culture supernatant (A) and cell surface expression of the inhibitory molecules PD-L1 or 733 
PD-L2 (B) were quantified. Data are presented as box-and-whisker plots with the median 734 
value and max/min values illustrated. The Mann–Whitney U test was used for the statistical 735 
analysis (*p<0.05 B. longum 35624 versus the sEPSneg strain). (C) THP-1 NF-κB activation 736 
following exposure to increasing concentrations of B. longum 35624 or its isogenic derivative 737 
sEPSneg (n=4 experimental replicates). (D) Activation of NF-κB in MDDCs exposed to B. 738 
longum 35624 or its isogenic derivative sEPSneg  (n=3, 50 bacteria:1 MDDC) . Statistical 739 
significance was determined using two-way ANOVA (*p<0.05 B. longum 35624 versus the 740 
sEPSneg strain). 741 
 742 
Figure 4. sEPSneg is not protective in a T cell transfer colitis model 743 
Following receipt of CD4+CD25-CD45RBhi T cells, C.B-17 SCID mice were orally 744 
administered B. longum 35624 (n=8), sEPScomp (n=8) or sEPSneg (n=8) strains. (A)  Weight 745 
loss and disease activity were monitored over time. Statistical significance was determined 746 
using two-way ANOVA (*p<0.05). (B) Following euthanasia, the colon:body weight ratio 747 
was determined. A representative picture of colons from B. longum 35624 or sEPSneg –treated 748 
animals is provided. (C) The percentage of IL-17+, IFN-γ+ and IL-10+ lymphocytes from 749 
mesenteric lymph nodes are illustrated (n=8 per group). Data are presented as box-and-750 
whisker plots with the median value and max/min values illustrated. Statistical significance 751 
was determined using the Kruskal–Wallis test and Dunn’s multiple comparison test (*p<0.05 752 
sEPSneg strain versus the other strains). 753 
 754 
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Figure 5. sEPSneg promotes TH17 responses in the lung 755 
Non-sensitized animals received an OVA aerosol challenge and were intranasally 756 
administered  PBS (Control, n=8). Sensitized animals received an OVA aerosol challenge and 757 
were intranasally administered  PBS (OVA, n=8), or intranasally administered  B. longum 758 
35624  (OVA & 35624, n=8), or intranasally administered  sEPSneg (OVA & sEPSneg, n=8). 759 
(A) The percentage of IL-17+ CD3+CD4+ T lymphocytes, isolated from lung tissue, and 760 
secretion of IL-17 from isolated lung cells re-stimulated ex vivo with OVA or LPS. Similarly, 761 
IFN-γ+ and IL-10+ CD3+CD4+ T lymphocytes and ex vivo IFN-γ and IL-10 secretion were 762 
quantified using identical methods, (B) and (C) respectively. Data are presented as box-and-763 
whisker plots with the median value and max/min values illustrated. Statistical significance 764 
was determined using the Kruskal–Wallis test and Dunn’s multiple comparison test (*p<0.05 765 
compared to the OVA group).766  on
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 Table 1. Bacterial strains and plasmids used in this study. 767 
Strain or plasmid Relevant characteristics Reference or source 
Strains   
E. coli EC101 Cloning host, repA-, Kmr Law et al., 1995 (26) 
E. coli XL1blue Cloning host, , Tetr Stratagene 
E. coli EC101 pNZ-M.1185 E. coli EC101 harbouring pNZ-M.1185 This study 
B. longum 35624 Parent strain Alimentary Health 
sEPSneg B. longum 35624 harbouring insertion mutation in 
priming glycosyl transferase encoding gene, pgt624 
This study 
sEPScomp sEPSneg harbouring pBC1.2_pgt624+BI0343 This study 
Plasmids   
pNZEm Gene expression vector, Emr Margolles et al., 2006 (56) 
pORI19 Emr, repA-, ori+, cloning vector Law et al., 1995 (25) 
pORI19tet(w)_pgt pORI19 harbouring internal fragment of BI0342 
(pgt) and tetW gene 
This study 
pBC1.2 E. coli –Bifidobacterial shuttle vector Álvarez-Martín et al., 2007 
(27) 
pBC1.2_pgt624+BI0343 pBC1.2 harbouring the cotranscribed genes 
pgt624+BI0343 under the control of their native 
promoter 
This study 
pNZ-M.1185 BI1185 (M.1185, isoschizomer of M.EcoRII) 
cloned with its own promoter in pNZEM 
This study 
 768 
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Table 2. Oligonucleotide primers used in this study are described. 770 
Purpose Primer Sequencea 
Cloning of M.1185 in 
pNZEm 
BI1185F_PstI GACTGCAGGCCCACTAGGTAACCAAACG 
BI1185R_SpeI GCGCACTAGTCTAGAGCAAAGCCAGTATAG 
   
Cloning of internal 583 bp 
fragment of pgt in pORI19 
BI0342F_HindIII GATAAGCTTGCGTCGGCAACTCAACTACC 
BI0342R_XbaI GATTCTAGACGTCGGCGTTCACTACCATC 
 
Cloning of pgt624+BI0343 
in pBC1.2 
 
BI0342FSalI 
 
GACGTCGACACTCCACTCTCGCTGATCG 
BI0343EcoRI GGCGAATTCTAATCAACCAAGGGGGTCTG 
   
  
a Restriction sites incorporated into oligonucleotide primer sequences are indicated in bold 771 
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